Fig. 2: Inhibiting miR-17-20a decreases ischemic muscle revascularization in experimental PAD. | Communications Medicine

Fig. 2: Inhibiting miR-17-20a decreases ischemic muscle revascularization in experimental PAD.

From: Inhibiting anti-angiogenic VEGF165b activates a miR-17-20a-Calcipressin-3 pathway that revascularizes ischemic muscle in peripheral artery disease

Fig. 2

a Laser Doppler perfusion imaging of microvascular blood flow in the ischemic muscle treated with a combination of miR-17, miR-20a inhibitor (miR-17-20a-Inh, pink box plots), or control inhibitor (Neg-Inh, blue box plot). n = 7. Repeated-measures Two-way ANOVA with Bonferroni’s post-test. b Immunohistochemical analysis of SMA (green) and CD31 (red) in ischemic gastrocnemius muscle treated with Neg-Inh (blue bars) or miR-17-20a-Inh (pink bars) at day 21 post-HLI. n = 7. Unpaired t-test. Scale bars are 50 µm. c Immunohistochemical analysis of CD31 (red) and PCNA (green) in ischemic gastrocnemius muscle treated with Neg-Inh (blue bars) or miR-17-20a-Inh (pink bars) at day 21 post-HLI. n = 7. Unpaired t-test. Scale bars are 50 µm. Outliers were removed by performing the Grubbs test. P < 0.05 significant. Data from the biological replicates are presented as mean ± standard error.

Back to article page